|
|
||||||||
ERRATUM |
1 Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark2 Faculty of Health Sciences, University of Aarhus, Aarhus, Denmark3 Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark and 4 Department of Endocrinology, University of Lund, S-20502 Malmo, Sweden
(Correspondence should be addressed to S S Lund; Email: sqrl{at}steno.dk)
The authors and the journal apologise for errors in the above paper which appeared in 158 (1) 35–46. In this paper, on page 38, under the results section, the first sentence of the second paragraph should read as follows:
At enrolment, 29 (30%) patients received lipid-lowering treatment as concomitant non-study medication (statin therapy, n=22 (23%) – hereof 20 patients (21%) during the entire study period; fish oil, n=8 (8%); acipimox, n=1 (1%); none of the patients received fibrates).
On page 40, in the results section under the heading Subgroups of patients according to ongoing statin treatment, pre-study antihyperglycaemic treatment regimens or known macrovascular disease the first sentence should read as follows:
Without fasting adjustment: statin treatment (n=18): –0.39 mmol/l (–0.62; –0.17), P=0.001; no statin treatment (n=55): –0.16 mmol/l (–0.29; –0.02), P=0.021; fasting adjusted: statin treatment (n=18): –0.25 mmol/l (–0.38; –0.12), P<0.001; no statin treatment (n=54): –0.08 mmol/l (–0.15; –0.00), P=0.041).
On page 39 and on page 41, Tables 2 and 3 should appear as follows:
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |